News

Aptinyx’s investigational therapy NYX-458 failed to be superior to a placebo at improving cognitive function in people with dementia due to Parkinson’s disease or Lewy body dementia in a Phase 2 clinical trial. These findings prompted the company to stop development work on NYX-458. “We are very disappointed…

Jotrol, Jupiter Neuroscience’s oral formulation of resveratrol, significantly improved muscle strength, motor coordination, and behavior in a mouse model of Parkinson’s disease, the company reported. “This research demonstrates the neuroprotectant abilities of Jotrol as a potential treatment to prevent onset and progression of PD [Parkinson’s] symptoms,” said Alison…

People living in areas with high levels of an air pollutant called fine particulate matter (PM2.5) — whose sources include power plants, motorized vehicles, and fires — are at greater risk of Parkinson’s disease, according to a U.S. study. “We found a nationwide association between Parkinson’s disease and air pollution…

Using a roundworm animal model, researchers identified a crucial mechanism for how signals from the environment can be combined with genetic susceptibility to influence the development of Parkinson’s disease. Mutations in the TNK2 gene, which have been reported in people with familial Parkinson’s, were found to lead to…

Insightec’s incision-free brain “surgery” technology — Exablate Neuro — leads to significant and sustained reductions in tremors, mobility problems, and other motor symptoms in advanced Parkinson’s disease patients with a fluctuating response to standard medications. That’s according to one-year data from a pivotal trial (NCT03319485) that tested the…

Havas Health Plus and the American Parkinson Disease Association (APDA) have launched a guide to intimacy meant to help Parkinson’s patients and their partners deepen their connections and improve their sexual life. Sexual dysfunction is common among people with Parkinson’s, and other symptoms such as rigidity,…

C4X Discovery (C4XD) has launched PatientSeek, a precision medicine platform that can help identify which people, including those with Parkinson’s disease, will likely benefit most from new therapies, based on their genetics. The launch follows a research collaboration with the Garvan Institute of Medical Research, Australia, which validated…

Women using a specific type of blood cholesterol-lowering medication, called lipophilic statins, for at least five years may have a lower risk of developing Parkinson’s disease, according to data from more than 70,000 women followed for 15 years in France. The results showed a dose-dependent effect, with lower Parkinson’s…

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded a second $500,000 grant to NRG Therapeutics supporting more research into its potential disease-modifying therapy for Parkinson’s disease. The new funding comes after the successful completion of a previous MJFF-funded project that set out to investigate how NRG’s small…

Among several atypical antipsychotics, Nuplazid (pimavanserin) seems to be the most effective at easing Parkinson’s disease psychosis (PDP) while sparing motor function, according to a review study. Clozapine, used off-label in people with Parkinson’s, also helped, but its effect was not as large and patients were more…